

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10647068	
	Filing Date		2003-08-22	
	First Named Inventor	Argenta, et al.		
	Art Unit	3733		
	Examiner Name	PHILOGENE, PEDRO		
Attorney Docket Number		0101-P02977US1		

U.S. PATENTS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6936037		2005-08-30	Bubb	
	2	6951553		2005-10-04	Bubb	
	3	7169151		2007-01-30	M. Lylinas	

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						<a href="#">Remove</a>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030225347		2003-12-04	L.C. Argenta	
	2	20040039391		2004-02-26	L.C. Argenta	
	3	20040064132		2004-04-01	Boehringer	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

4	20040073151		2004-04-15	Weston	
5	20040122434		2004-06-24	L.C. Argenta	
6	20040039415		2004-02-26	D.S. Zamierowski	
7	20050020955		2005-01-27	T.B. Sanders	
8	20050177190		2005-08-11	D.S. Zamierowski	
9	20050182445		2005-08-18	D.S. Zamierowski	
10	20050234510		2005-10-20	D.S. Zamierowski	
11	20050240220		2005-10-27	D.S. Zamierowski	
12	20060079852		2006-04-13	S.K. Bubb	

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

**FOREIGN PATENT DOCUMENTS**

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
-------------------	---------	--------------------------------------	-----------------------------	------------------------	------------------	---	--	----------------

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

1						<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button <a href="#">Add</a>						
<b>NON-PATENT LITERATURE DOCUMENTS</b>						<a href="#">Remove</a>
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>5</sup>
	1	KCI v. BlueSky, Rebuttal Expert Report of Wilson C. Hayes, Ph.D. In Response to the Report of Michael H. Baniak, (February 18, 2005). BS-14				<input type="checkbox"/>
	2	KCI v. BlueSky, Expert Report of John T. Goolkasian in Rebuttal to Report of Michael H. Baniak, with Exhibits, (February 18, 2005). BS-15				<input type="checkbox"/>
	3	KCI v. BlueSky, Rebuttal Expert Report of Louis C. Argenta, M.D. to Expert Report of Michael H. Baniak, (February 18, 2005). BS-16				<input type="checkbox"/>
	4	Opposition to Patent EP 0,688,189 - New European patent specification EP 0,688,189 B2; Date of publication and mention of the opposition decision: June 1, 2005. EPOPWH2-01				<input type="checkbox"/>
	5	Opposition to EP 0,688,189 - Notice of opposition to European patent no. 0,688,189 by Mondomed N.V., and letter to EPO, 12 pp. (dated June 12, 2001) EPOPWH2-02				<input type="checkbox"/>
	6	3M Ioban 2, Breathability, Conformability and Strength, Breathability - Moisture Vapor Transmission Rate and Conformability and Strength - Tensile Strength, Elongation and Fn Modulus Test (1 sheet). NPL-001				<input type="checkbox"/>
	7	ACU-derm® Transparent Moisture Vapor Permeable Polyurethane Dressing, (14 sheets). NPL-003				<input type="checkbox"/>
	8	Aeros, "Moblvac II", (1 sheet). NPL-004				<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

9	BANWELL, P E., et al., "Topical negative pressure (TNP): the evolution of a novel wound therapy," J. Wound Care, 12 (1):22-8 (January 2003). NPL-035	<input type="checkbox"/>
10	BARILLO, D., et al., "Management of burns to the hand", Wounds 2003, 15(1):4-9, Health Management Publications, Inc., (11 sheets) (Posted 02/12/2003). NPL-037	<input type="checkbox"/>
11	CARDOZO, M., "A case study of holistic wound management in intensive care", Br. J. Nurs., 12(11 Suppl):S35-37, S40-42 (June 2003). NPL-069	<input type="checkbox"/>
12	CHARIKER-JETER® Wound Drainage Kit Instructions, Item #500.7777, BlueSky Medical, 2 pp. NPL-076	<input type="checkbox"/>
13	CHARIKER-JETER® Wound Drainage Kit, BlueSky Medical, and Wooding-Scott® Drainage/Irrigation Kit, 2 page advertisement with copy of business card from Quality Medical Supply. NPL-077	<input type="checkbox"/>
14	CHARIKER-JETER® Wound Sealing Kit, Wound Application Instructions, 1 page advertisement. NPL-078	<input type="checkbox"/>
15	COLLIER, M., "Topical negative pressure therapy", Nurs. Times, 99(5):54-5 (February 4-10, 2003). NPL-091	<input type="checkbox"/>
16	COOK PNEUMOTHORAX CATHETER SET, WAYNE PNEUMOTHORAX CATHETER SET, Emergency Medicine, Videotape advertisement. (3 pp.) NPL-094	<input type="checkbox"/>
17	COOPER, D., "Wound Healing", Nurs. Clin. N. Am., 25(1):163-164 (March 1990). NPL-096	<input type="checkbox"/>
18	COYLE, M.B., et al., "A case study: positive outcomes to negative pressure wound therapy -- a collaborative assessment", Hospital of Saint Raphael, 1 page chart. NPL-102	<input type="checkbox"/>
19	DEKNATEL, Div. Of Howmedica, Inc. Queens Village, NY 11429. "Pleur-evac." NPL-111	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

20	DOMKOWSKI, P.W., et al., "Evaluation of vacuum-assisted closure in the treatment of poststerotomy mediastinitis," J. Thorac. Cardiovasc. Surg., 126(2):386-90 (August 2003). NPL-119	<input type="checkbox"/>
21	Dow Corning Silasbo® Foam Dressing: A New Concept in the Management of Open Granulating Wounds, 2 pp. of advertisements. NPL-121	<input type="checkbox"/>
22	DuoDERM™ Hydroactive™ Dressing, "In wound management – Now, a proven environment for fast healing", 1 page advertisement. NPL-126	<input type="checkbox"/>
23	EDLICH, R.F., et al., "Surgical devices in wound healing management", Wound Healing: Biochemical and Clinical Aspects, pp. 581-599 (1992). NPL-131	<input type="checkbox"/>
24	EGINTON, M.T., et al., "A prospective randomized evaluation of negative-pressure wound dressings for diabetic foot wounds", Ann. Vasc. Surg., 17(6):645-9 (2003). NPL-132	<input type="checkbox"/>
25	EISENBUD, D.E., "Dressings" in Modern wound management, Anadem Publishing, pp. 109-116 (January 1999). NPL-134	<input type="checkbox"/>
26	EMERSON, J. H. Emerson Co., "Emerson Transport Suction Unit", 1 sheet of advertisement. NPL-138	<input type="checkbox"/>
27	EMERSON, Series 55, "Emerson post-operative suction pumps", 1 sheet of advertisement. NPL-139	<input type="checkbox"/>
28	ERDMANN, D., et al., "Abdominal wall defect and enterocutaneous fistula treatment with the vacuum-assisted closure (VAC) system", Plast. Reconstruct. Surg., 108(7):2066-8 (December 2001). NPL-141	<input type="checkbox"/>
29	FERREIRA, M.C., et al., "The vacuum assisted closure of complex wounds: report of three cases", Rev. Hosp. Clin. Fac. Med. S. Paulo, 58(4):227-30 (2003). NPL-151	<input type="checkbox"/>
30	FISHER, A., et al., "Vacuum assisted wound closure therapy", Issues Emerg. Health Technol., Issue 44, 6 pp. (March 2003). NPL-154	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

31	GRAMS ASPIRATOR, et al., Grams Medical, catalog pp. (3 pp.) (prices as of August 1991 and September 1992). NPL-175	<input type="checkbox"/>
32	GREER, S.E., "Whither subatmospheric pressure dressing?" Ann. Plast. Surg., 45(3):332-336 (April 2000). NPL-180	<input type="checkbox"/>
33	HALLBERG, H., et al., "Vaginal construction with skin grafts and vacuum-assisted closure", Scand. J. Plast. Reconstr. Surg. Hand Surg., 37(2):97-101 (2003). NPL-184	<input type="checkbox"/>
34	HARGENS, A.R., et al., "Control of circulatory function in altered gravitational fields", Physiologist, 35(1 Suppl.):S80-3 (4 sheets) (February 1992). NPL-189	<input type="checkbox"/>
35	HERRMANN, L.G., et al., "The conservative treatment of arteriosclerotic peripheral vascular diseases: passive vascular exercises (pavaex therapy)", Ann. Surg., 100(4): 750-760 (October 1934). NPL-199	<input type="checkbox"/>
36	HESS, C.L., et al., "A review of mechanical adjuncts in wound healing: hydrotherapy, ultrasound, negative pressure therapy, hyperbaric oxygen, and electrostimulation", Ann. Plast. Surg., 51(2):210-8 (August 2003). NPL-204	<input type="checkbox"/>
37	HILSABECK, J.R., "The presacral space as a collector of fluid accumulations following rectal anastomosis: tolerance of rectal anastomosis to closed suction pelvic drainage", Dis. Colon Rectum, 25(7):680-684 (October 1982). NPL-206	<input type="checkbox"/>
38	HODZIC, J., et al., "Vacuum sealing of extensive wound healing disorders after kidney transplantation," Urologe A., (6 sheets in German, English abstract on page 2 and 1 sheet printout from PubMed); 42(8):1097-100 (August 2003) (Epub April 3, 2003). NPL-208	<input type="checkbox"/>
39	Howmedica porto-vac®, "Gentle, Steady Wound Drainage", 1 page advertisement. NPL-212	<input type="checkbox"/>
40	Industrial Equipment News, P.O. Box 1158, Skokie, IL 60076-9786, (1 sheet). NPL-218	<input type="checkbox"/>
41	Instruction Manual, Creative Medical Laboratories, Inc. P.O. Box 6347, Rochester, Minn. 55903. "TUGS" (Transportable Universal Gradient Suction) (7 sheets). NPL-221	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

42	KAUFMAN, M.W., et al., "Vacuum-assisted closure therapy: wound care and nursing implications", Dermatol. Nurs., 15 (4):317-20, 323-236 (August 2003). NPL-232	<input type="checkbox"/>
43	KRASNER, D.L., "Managing wound pain in patients with vacuum-assisted closure devices", Ostomy Wound Manage., 48(5):38-43 (May 2002). NPL-243	<input type="checkbox"/>
44	LAMKE, L.O., et al., "The evaporative water loss from burns and the water-vapour permeability of grafts and artificial membranes used in the treatment of burns", Burns, 3(3):159-165 (March 1977). NPL-247	<input type="checkbox"/>
45	LANDIS, E.M., et al., "The effects of alternate suction and pressure on blood flow to the lower extremities", J. Clin. Invest., 12(5):525-561 (September 1933). NPL-249	<input type="checkbox"/>
46	LANGWORTHY, M., et al., "Treatment of the mangled lower extremity after a terrorist blast injury", Clin. Orthop. Relat. Res., (422):88-96 (May 2004). NPL-251	<input type="checkbox"/>
47	LUCKRAZ, H., et al., "Vacuum-assisted closure as a treatment modality for infections after cardiac surgery", J. Thorac. Cardiovasc. Surg., 125(2):301-5 (February 2003). NPL-260	<input type="checkbox"/>
48	MADDIN, W.S., et al., "The biological effects of a pulsed electrostatic field with specific reference to hair: electrotrichogenesis", Int. J. Dermatol., 29(6):446-450 (July - August 1990). NPL-263	<input type="checkbox"/>
49	Manuslectric Breastpump, Catalog pp. (4 pp.). NPL-266	<input type="checkbox"/>
50	McCULLOCH, J.M., et al., "Vacuum-compression therapy for the treatment of an ischemic ulcer", Phys. Ther., 73 (3):165-9 (March 1993). NPL-270	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10647068
Filing Date	2003-08-22
First Named Inventor	Argenta, et al.
Art Unit	3733
Examiner Name	PHILOGENE, PEDRO
Attorney Docket Number	0101-P02977US1

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Niels Haun/	Date (YYYY-MM-DD)	2007-05-07
Name/Print	Niels Haun	Registration Number	48,488

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.